Download presentation
Presentation is loading. Please wait.
Published byΜέντωρ Βαρουξής Modified over 6 years ago
1
Topotecan/Cisplatin Compared with Cisplatin/Etoposide as First-Line Treatment for Patients with Extensive Disease Small-Cell Lung Cancer: Final Results of a Randomized Phase III Trial Thomas H. Fink, MD, Rudolf M. Huber, MD, David F. Heigener, MD, Corrina Eschbach, MD, Cornelius Waller, MD, Ernst U. Steinhauer, MD, Johann C. Virchow, MD, Frank Eberhardt, MD, Hans Schweisfurth, MD, Michael Schroeder, MD, Thomas Ittel, MD, Simone Hummler, MD, Norbert Banik, PhD, Thomas Bogenrieder, Thomas Acker, Martin Wolf, MD Journal of Thoracic Oncology Volume 7, Issue 9, Pages (September 2012) DOI: /JTO.0b013e318260de75 Copyright © 2012 International Association for the Study of Lung Cancer Terms and Conditions
2
Figure 1 Number of evaluable patients. TP, topotecan-cisplatin; PE, Physical examination; TE, topotecan-etoposide. Journal of Thoracic Oncology 2012 7, DOI: ( /JTO.0b013e318260de75) Copyright © 2012 International Association for the Study of Lung Cancer Terms and Conditions
3
Figure 2 Kaplan–Meier estimates for survival in the per-protocol population. PE, physical examination; TP, topotecan-cisplatin. Journal of Thoracic Oncology 2012 7, DOI: ( /JTO.0b013e318260de75) Copyright © 2012 International Association for the Study of Lung Cancer Terms and Conditions
4
Figure 3 Kaplan–Meier estimates for time to progression in the intention-to-treat population. PE, physical examination; TP, topotecan-cisplatin. Journal of Thoracic Oncology 2012 7, DOI: ( /JTO.0b013e318260de75) Copyright © 2012 International Association for the Study of Lung Cancer Terms and Conditions
Similar presentations
© 2025 SlidePlayer.com. Inc.
All rights reserved.